Zydus Lifesciences bags USFDA nod for acne cream Tretinoin
Ahmedabad: Zydus Lifesciences Limited has announced that the Company has received final approval from the United States Food and Drug Administration (USFDA) to market Tretinoin Cream USP, 0.1%, (USRLD: Retin-A Cream, 0.1%).
Tretinoin cream is used to treat acne. The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad (India).
Tretinoin Cream USP, 0.1% had annual sales of USD 54.8 mn in the United States (IQVIA MAT Feb-24). The group now has 394 approvals and has so far filed over 460* ANDAs since the commencement of the filing process in FY 2003-04. (*as of 31st December 2023).
Read also: Zydus Gets CDSCO Panel Nod To Manufacture Market Letermovir 240 mg, 480 mg Tablet
Medical Dialogues team had earlier reported that Zydus Lifesciences had received final approval from the USFDA for Clindamycin Phosphate Gel USP, 1% (USRLD: Cleocin T Gel, 1%). Clindamycin Phosphate Gel USP, 1% is used to treat acne. It helps to decrease the number of acne lesions. Clindamycin is an antibiotic which works by stopping the growth of bacteria.
Read also: Zydus bags USFDA nod for acne gel Clindamycin Phosphate
Headquartered in Ahmedabad, Zydus Lifesciences Limited is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer-related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs. The group employs over 26,000 people worldwide, including 1,400 scientists engaged in R&D.
Read also: New Drug Application of Zydus Desidustat tablets by China Medical System Holdings accepted in China
